Endo Health Solutions (Nasdaq: ENDP) today announced that NuPathe Inc. (NASDAQ: PATH) has terminated its merger agreement with Endo. Endo has received a $5 million termination fee from NuPathe. "We believe that the agreement NuPathe has ...
NuPathe has received a notice for additional US patent allowance to cover methods for treating migraine patients using an iontophoretic patch containing a triptan without irritating the patient's skin. Expected to be issued in the next ...
Tags: Migraine Therapy, Medicine
US based NuPathe announced that its New Drug Application (NDA) resubmission for its migraine patch (NP101) has been accepted for filing by the US Food and Drug Administration (FDA). Migraine Patch (NP101 or Zelrix) is an active, ...
Tags: FDA, NuPathe, migraine patch, NDA